Filing Details

Accession Number:
0001140361-14-026909
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-06-27 17:31:22
Reporting Period:
2014-06-25
Filing Date:
2014-06-27
Accepted Time:
2014-06-27 17:31:22
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1031927 Echo Therapeutics Inc. ECTE Electromedical & Electrotherapeutic Apparatus (3845) 411649949
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1120642 Uri Landesman 30 00 47Th Ave
Long Island City NY 11101
No No Yes No
1299265 Platinum Partners Value Arbitrage Fund, Lp C/O Walkers Corporate Services Limited
Walker House, 87 Mary Street
Georgetown, Grand Cayman E9 KY1-9002
No No Yes No
1339643 Mark Nordlicht 152 West 57Th Street
4Th Floor
New York NY 10019
No No Yes No
1368616 Platinum Management (Ny) Llc 152 West 57Th Street
New York NY 10019
No No Yes No
1404598 Platinum-Montaur Life Sciences, Llc 152 West 57Th Street
4Th Floor
New York NY 10019
No No Yes No
1476165 L.p. Fund Master Opportunity Liquid Partners Platinum 152 West 57 Street, 4Th Floor
New York NY 10019
No No Yes No
1582140 Platinum Liquid Opportunity Management (Ny) Llc 152 West 57Th Street
4Th Floor
New York NY 10019
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-06-25 2,300 $2.20 597,713 No 4 P Indirect By Platinum Partners Liquid Opportunity Master Fund L.P.
Common Stock Acquisiton 2014-06-26 15,000 $2.20 612,713 No 4 P Indirect By Platinum Partners Liquid Opportunity Master Fund L.P.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By Platinum Partners Liquid Opportunity Master Fund L.P.
No 4 P Indirect By Platinum Partners Liquid Opportunity Master Fund L.P.
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 1,605,424 Indirect By Platinum Partners Value Arbitrage Fund L.P.
Footnotes
  1. This Form 4 is filed jointly by Platinum Partners Value Arbitrage Fund L.P. ("PPVA"), Platinum Partners Liquid Opportunity Master Fund L.P. ("PPLO"), Platinum-Montaur Life Sciences, LLC ("Platinum-Montaur"), Platinum Management (NY) LLC ("Platinum Management"), Platinum Liquid Opportunity Management (NY) LLC ("Platinum Liquid Management"), Mark Nordlicht and Uri Landesman (collectively, the "Reporting Persons"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the shares of Common Stock reported herein except to the extent of his or its pecuniary interest therein.
  2. Securities owned directly by PPLO. Each of Platinum Liquid Management, as the Investment Manager of PPLO, and Mark Nordlicht and Uri Landesman, as the Chief Investment Officer and President, respectively, of Platinum Liquid Management, may be deemed to beneficially own the securities owned directly by PPLO.
  3. Securities owned directly by PPVA. Each of Platinum Management, as the Investment Manager of PPVA, and Mark Nordlicht and Uri Landesman, as the Chief Investment Officer and President, respectively, of Platinum Management, may be deemed to beneficially own the securities owned directly by PPVA.